FDA: Page 81
-
Hearing industry calls Bose self-fit hearing aid study flawed in complaint to FDA
The Hearing Industries Association letter argues the device's Phase II clinical study "does not provide enough evidence of effectiveness of the self-fitting method given the study's initial reliance on professionals for fitting."
By David Lim • Aug. 15, 2019 -
Abbott poised to profit from CMS review of TMVR coverage
Analysts at Cowen estimate CMS coverage in a newly considered indication could triple the number of patients eligible for transcatheter mitral valve repair.
By Nick Paul Taylor • Aug. 15, 2019 -
Explore the Trendline➔
Courtesy of Intuitive Surgical
TrendlineTop 5 stories from MedTech Dive
From the top medtech trends to watch in 2026 to haphazard layoffs at the Food and Drug Administration and the evolving use of AI in the medtech sector, here is a collection of top stories from MedTech Dive.
By MedTech Dive staff -
Industry backs Australia's device identifier plan with caveats
The responses showed broad support for a unique device identification system based on global guidelines, but the Therapeutic Goods Administration also faced some pushback from J&J and Roche.
By Nick Paul Taylor • Aug. 15, 2019 -
Australia weighs in on paclitaxel-coated balloons
The Therapeutic Goods Administration said data on adverse events in Australia haven't shown a signal like the one described by FDA.
By Susan Kelly • Aug. 13, 2019 -
USTR: 10% tariffs on 'certain' electronics from China delayed to Dec. 15
Chinese imports not included on USTR's forthcoming list will still face 10% duties on Sept. 1, as President Donald Trump announced earlier this month.
By Shefali Kapadia • Updated Aug. 13, 2019 -
Concept Medical nabs breakthrough designation for sirolimus-coated balloon for PAD
If granted FDA marketing authorization, the device may compete with paclitaxel devices sold by BD, Medtronic, Boston Scientific, Philips and Cook Medical.
By David Lim • Aug. 13, 2019 -
China grants innovative device designation to Novocure's Optune
Novocure's Chinese partner now gets the opportunity for more contact with regulators and an expedited review in a market estimated at $96.3 billion this year, up from $53.6 billion in 2016.
By Nick Paul Taylor • Aug. 13, 2019 -
CMS rejects industry bid to boost payments for device-based opioid alternatives
The agency said evidence submitted was plagued by potential conflicts of interest, inadequate sample sizes and lack of peer review.
By David Lim • Aug. 12, 2019 -
Wright Medical rocked by distributor disinterest and staff losses
"We will be bringing more knife fighters to the knife fight and having more motivated knife fighters in the knife fight," CEO Robert Palmisano said of a rivalry over sales reps.
By Nick Paul Taylor • Aug. 8, 2019 -
FDA grants breakthrough status to Perfuze stroke device
The startup is attempting to enter a field fought over by Johnson & Johnson, Medtronic and Stryker.
By Nick Paul Taylor • Aug. 8, 2019 -
FDA to update paclitaxel device labels with mortality signal warning
The agency and manufacturers such as BD, Medtronic and Boston Scientific are planning research into the devices' long-term safety profile using new randomized trials and registry datasets.
By David Lim • Updated Aug. 8, 2019 -
iCubate lung infection test secures FDA breakthrough status
The in vitro diagnostics maker said it can accelerate diagnosis and treatment of a disease that affects more than 80,000 people in the U.S.
By Nick Paul Taylor • Aug. 7, 2019 -
US to slap 10% tariffs on $300B in Chinese goods as medtech seeks details
The tariffs are set to take effect on Sept. 1. AdvaMed said it "strongly opposes tariffs by both sides on medical technology products" and is lobbying U.S. trade negotiators.
By Shefali Kapadia • Aug. 2, 2019 -
Japan to reimburse TransEnterix's robotic surgery system
The decision positions the company to compete with Intuitive Surgical in one of the largest markets for the platforms.
By Nick Paul Taylor • Aug. 2, 2019 -
UnitedHealthcare's depression test decision boosts Myriad's prospects
While Medicare only permits psychiatrists to order the test, the private payer will reimburse requests from all providers.
By Nick Paul Taylor • Aug. 2, 2019 -
FDA grants breakthrough status to Procyrion's cardiac device
Procyrion's Aortix aims to offer physicians a minimally invasive, lower-risk alternative to left ventricular assist devices when treating patients with acute decompensated heart failure and worsening renal function.
By Nick Paul Taylor • Aug. 1, 2019 -
FDA announces fiscal 2020 device user fee rates
The fees, which cover medical device registration, submissions and certain periodic reports, show slight increases from the 2019 rates.
By Susan Kelly • July 31, 2019 -
CMS pilot to give doctors patient Medicare claims data
CMS hopes to eventually roll out the initiative to all Medicare fee-for-service providers, giving doctors Medicare claims data for their patients, including prescribed medications, procedures, diagnoses and other providers.
By David Lim • July 30, 2019 -
CMS pitches add-on payment for new renal care tech, DME fee adjustments
The agency projects total payments to hospital-based ESRD facilities to rise 1.9% year to year while payments to freestanding renal care facilities like DaVita and Fresenius are set to increase 1.5%.
By David Lim , Maria Rachal • July 30, 2019 -
FDA clears Lyme disease tests, ending reliance on immunoblots
Zeus Scientific won the clearances after convincing the agency using enzyme immunoassays alone is as accurate as the current two-tiered approach.
By Nick Paul Taylor • July 30, 2019 -
Australia on watch for possible EU notified body shortage
The country's Therapeutic Goods Administration has issued new guidance to aid device makers seeking overseas marketing authorization.
By Susan Kelly • July 29, 2019 -
FDA finalizes biliary stent guide after Cook, Boston Scientific feedback
The final guidance hews closely to the draft released for consultation last year, despite Cook calling for a variety of changes.
By Nick Paul Taylor • July 26, 2019 -
Edwards discontinues Centera valve, goes all in on Sapien 3 TAVR line
Executives said the company anticipates FDA will approve the transcatheter aortic valve replacement product for patients with low surgical risk during the third quarter.
By David Lim • July 24, 2019 -
FDA directly links Allergan Biocell breast implants with cancer risk, prompting recall
"FDA took action to alert the firm to new evidence indicating a recall is warranted to protect women's health," Principal Deputy Commissioner Amy Abernethy wrote Wednesday regarding Allergan's Biocell textured devices.
By Nick Paul Taylor • July 24, 2019 -
Titan Medical warns robotic surgery filing target may slip
The Canadian medtech called the regulatory filing schedule "very tight" and "not completely within [its] control."
By Nick Paul Taylor • July 24, 2019
Previous
